Loading…
IVERMECTIN is a brand name for Ivermectin. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: • Treatment of intestinal strongyloidiasis (anguillulosis). • Treatment of proven or suspected microfilaremia in patients with lymphatic filariasis caused by Wuchereria bancrofti. • Treatment of human sarcoptic scabies. Treatment is justified when the diagnosis of scabies has been established clinically and/or by…
Verbatim from this product's MHRA label. Tap a section to expand.
1. 4 Special warnings and precautions for use Special warnings Efficacy and dosing regimen of ivermectin in immunocompromised patients being treated for intestinal strongyloidiasis have not been established by adequate clinical studies.
There have been reported cases which show the persistence of infestation following a single dose of ivermectin particularly in this type of patients. Ivermectin is not a prophylactic therapy of infection with filariae or anguillulosis; there are no data available demonstrating the efficacy of ivermectin either for killing or preventing the maturation of infective larvae in humans.
Ivermectin has not been shown to have any activity against the adult worm of any species of Filariae. Ivermectin has not been shown to have any beneficial effect on tropical pulmonary eosinophilia syndrome on lymphadenitis or lymphangitis observed in case of infection with filariae.
Following administration of ivermectin, the intensity and severity of adverse experiences are probably related to the pretreatment microfilarial density particularly in the blood. In patients co- infected with Loa loa, microfilarial density, particularly in the blood, is most often high which predisposes the treated patients to an increased risk in the occurrence of serious adverse experiences.
CNS adverse experiences (encephalopathies) have been rarely reported in patients treated with ivermectin and co-infected by a high number of microfilariae of Loa loa. 8). Neurological toxicity, including depressed level of consciousness and coma, has also been reported in patients with the use of ivermectin in the absence of Loa loa infection.
These events have generally resolved with supportive care and the discontinuation of ivermectin. 9). Concomitant treatment with DEC and ivermectin in mass chemotherapy campaigns for filariasis caused by Wuchereria Bancrofti in Africa is not recommended.
Co-infection with other microfilariae, such as Loa loa may result in high microfilaraemia in patients infected. Systemic exposure to DEC in such patients may result in the occurrence of serious side effects related to the rapid and effective microfilaricidal effects of this drug.
Following administration of drugs with a rapid microfilaricidal action such as diethylcarbamazine citrate (DEC) in patients with onchocerciasis, cutaneous and/or systemic reactions of varying severity (the Mazzotti reaction), and ophthalmological reactions have been reported.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ivermectin in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
These reactions are probably due to inflammatory responses to degradation products released following the death of microfilariae. Patients treated with ivermectin for onchocerciasis may also experience these reactions when treated for the first time.
After treatment with a microfilaricidal drug, patients with hyperreactive onchodermatitis or “Sowda” (observed particularly in Yemen) may be more likely than others to experience severe cutaneous adverse reactions (edema and aggravation of onchodermatitis).
8). At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, ivermectin should be withdrawn immediately and an alternative treatment considered.
If the patient has developed a severe cutaneous adverse reaction such as SJS or TEN with the use of ivermectin, treatment with ivermectin must not be restarted at any time. In the absence of convincing evidence of efficacy (and safety) for use of ivermectin as a treatment for COVID-19 it is strongly recommended that ivermectin is not used for the treatment of patients with or suspected to be infected with SARS-COV2 as this may lead to a delay in diagnosis and /or receiving appropriate treatment for COVID-19.
The extent and risks of such use will be monitored as part of the risk management plan. Precautions for use Safety in paediatric patients weighing less than 15 kg of body weight has not been established.